Impella approval opens up $3bn market for Abiomed
This article was originally published in Clinica
Executive Summary
Abiomed’s percutaneous heart pump Impella 2.5 has received premarket approval (PMA) from the US FDA, giving the company access to a US market potentially worth over $3bn, according to Jefferies analyst Raj Denhoy.